17279-56-0

Usage

Uses

Used in Pharmaceutical Industry:
(2-AMINO-4-PHENYL-THIAZOL-5-YL)-PHENYL-METHANONE is used as a precursor in the synthesis of new pharmaceutical compounds due to its distinctive molecular structure and potential pharmacological activities. Its unique features may contribute to the development of innovative drugs with novel mechanisms of action.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2-AMINO-4-PHENYL-THIAZOL-5-YL)-PHENYL-METHANONE serves as a valuable research tool for exploring its biological activities and potential therapeutic applications. Further studies on its synthesis and interaction with biological targets could lead to the discovery of new drugs with improved efficacy and safety profiles.
Used in Drug Development:
(2-AMINO-4-PHENYL-THIAZOL-5-YL)-PHENYL-METHANONE is utilized in drug development as a lead compound for the design and optimization of new therapeutic agents. Its unique structural features provide a foundation for the modification and enhancement of its pharmacological properties, potentially resulting in the creation of more effective and targeted medications.

InChI:InChI=1/C16H12N2OS/c17-16-18-13(11-7-3-1-4-8-11)15(20-16)14(19)12-9-5-2-6-10-12/h1-10H,(H2,17,18)

Upstream product

• 120-46-7 1,3-diphenylpropanedione 
• 17356-08-0 thiourea 
• 728-84-7 2-bromo-1,3-diphenylpropane-1,3-dione 
• 74280-88-9 (2S,3R)-phenyl-(3-phenylaziridin-2-yl)methanone 
• 1147550-11-5 ammonium thiocyanate 
• 80012-16-4 3-amino-1,3-diphenyl-2-propene-1-onate 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 17279-59-3 N-(5-benzoyl-4-phenyl-thiazol-2-yl)-acetamide 
• 1391979-80-8 2-[4-(ethylsulfonyl)phenyl]-N-{5-[hydroxy(phenyl)methyl]-4-phenyl-1,3-thiazol-2-yl}acetamide 
• 1363179-02-5 2-[3-(ethylsulfonyl)phenyl]-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363179-00-3 2-[2-(ethylsulfonyl)phenyl]-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363178-98-6 2-{4-[(2-hydroxyethyl)sulfonyl]phenyl}-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363178-96-4 2-(4-{[2-(methyloxy)ethyl]sulfonyl}phenyl)-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363178-94-2 N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]-2-[4-(propylsulfonyl)phenyl]acetamide 
• 1363178-92-0 N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yI]-2-{4-[(2,2,2-trifluoroethyl)sulfonyl]phenyl}acetamide 
• 1363178-86-2 2-[4-(ethylsulfonyl)phenyl]-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]propanamide 
• 1363178-84-0 2-[4-(ethylsulfonyl)phenyl]-2-methyl-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]propanamide 
• 919853-65-9 2-[4-(ethylsulfonyl)phenyl]-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363178-88-4 2-{4-[(methylamino)sulfonyl]phenyl}-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363178-90-8 2-{4-[(ethylamino)sulfonyl]phenyl}-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 941883-55-2 2-[4-(methylsulfonyl)phenyl]-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 

Relevant academic research and scientific papers

Solvent-Controlled Synthesis of Thiocyanated Enaminones and 2-Aminothiazoles from Enaminones, KSCN, and NBS

An effective and simple solvent-controlled synthesis of thiocyanated enaminones and 2-aminothiazoles has been demonstrated from enaminones, potassium thiocyanate, and N-bromosuccinimide. This process features mild reaction conditions, simple and easy oper

TBHP/AIBN-Mediated Synthesis of 2-Amino-thioazoles from Active Methylene Ketones and Thiourea under Metal-free Conditions

A new oxidative system of tert-butyl hydroperoxide (TBHP)/azodiisobutyronitrile (AIBN) has been used for the first time for a convenient, metal-free synthesis of substituted 2-aminothioazoles from active methylene ketone derivatives and thiourea. The reaction is postulated to proceed via an oxidative cyclization initiated by a radical process and followed by a condensation reaction.

Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools

The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX809 indicating a different mechanism of action. In an attempt to construct more interesting molecules, it was thought to generate chemically hybrid compounds, blending a portion of VX809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new molecules were tested in functional and biochemical assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity.

Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors

Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.

New one-pot approach to regio-synthesis of substituted 2-aminothiazoles from the corresponding keto-aziridines

Ring expansion of keto-aziridines to the corresponding 2-aminothiazoles (54-67 %) using ammonium thiocyanate in the presence of RuCl3 under refluxing acetonitrile is described. A plausible mechanism for the synthesis of substituted 2-aminothiazoles has been proposed.

NOVEL COMPOUNDS

Novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR? provided by the present invention.

COMPOUNDS USEFUL AS RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS

Disclosed are retinoid-related orphan receptor gamma (RORγ) modulators of Formula (I) and their use in the treatment of diseases mediated by RORγ, wherein the radicals have the meanings as defined in the invention.

UBIQUITIN LIGASE INHIBITORS

This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical p

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

THERAPEUTIC AGENT FOR CANCER

A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1? a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2? unsubstituted thiazol-2-yl group, or 3? unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ―CONH―E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.